GET DAILY SIGNALSAmgen (AMGN) Posts Solid Q3 Beat: Revenue +8% to $10.37 Billion, EPS +14%, Guidance Lifted
Key Takeaways
- Revenue rose 8% year over year to $10.37 billion, topping the roughly $10.05 billion consensus estimate.
- Adjusted earnings per share (EPS) climbed 14% to $6.45, comfortably ahead of the ~$5.76–$5.79 Wall Street consensus.
- GAAP net income reached $3.86 billion, or $7.08 per share, up 19% on a per-share basis from a year earlier.
- Full-year guidance was raised, with 2026 revenue now seen at $38.9–$39.7 billion and adjusted EPS at $22.90–$23.70.
- Growth engines delivered: Repatha rose 37%, Uplizna surged 191%, and Imdelltra jumped 128% year over year.
- Biosimilar pressure intensified, with Prolia down 45% and XGEVA down 47% as competition weighed on the bone-health franchise.
- For more detail on Amgen, you can review its Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- To discover AI-driven trading ideas across the broader market, explore Trending AI Robots.
Why These Results Matter
Amgen's third-quarter report offers a clear read on how the biotech giant is managing a pivotal transition. The company is simultaneously scaling newer medicines such as Repatha, Uplizna, Tezspire, and Imdelltra while absorbing steep erosion in legacy products like Prolia and Xgeva, which face growing biosimilar competition. Investors also track progress on MariTide, the experimental weight-loss drug that could reshape the company's long-term growth profile. Against this backdrop, the quarter tested whether Amgen's volume-driven momentum can outpace competitive headwinds and support its raised full-year outlook, making the results a key barometer for the stock's direction.
The Numbers Behind the Quarter
Amgen reported third-quarter total revenue of $10.37 billion, an 8% increase from the prior-year period and slightly above the roughly $10.05–$10.1 billion analyst consensus. Adjusted earnings per share came in at $6.45, up 14% year over year and well ahead of the ~$5.76–$5.79 Wall Street estimate, according to data from LSEG and FactSet. On a GAAP (Generally Accepted Accounting Principles) basis, net income totaled $3.86 billion, or $7.08 per share.
Performance was led by several growth products. Repatha sales rose 37% to about $1.09 billion, Evenity climbed 39% to $751 million, and Tezspire advanced 43% to $538 million. Uplizna surged 191% to $451 million, while the cancer therapy Imdelltra jumped 128% to $406 million. These gains were partly offset by biosimilar-driven declines: Prolia fell 45% to $632 million and Xgeva dropped 47% to $288 million. Amgen generated $3.7 billion in free cash flow, down from $4.2 billion a year earlier. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Management also raised its full-year 2026 outlook, now guiding to revenue of $38.9 billion to $39.7 billion and adjusted EPS of $22.90 to $23.70, with capital expenditures expected near $2.6 billion.
Market Response
Despite topping both revenue and earnings expectations, Amgen shares slipped in the immediate aftermath of the report, falling roughly 1.5% to 2% in after-hours trading. The muted reaction reflected investor focus on the sharp declines in Prolia and Xgeva, which underscored the growing competitive threat from biosimilars to two long-standing blockbuster franchises. While the strength of newer products and the raised guidance were viewed positively, concerns about the durability of the legacy bone-health business tempered enthusiasm. The market's response suggests investors are weighing near-term erosion against the company's emerging growth portfolio rather than rewarding the headline beat outright.
Forward Outlook and Key Factors to Monitor
Following the third-quarter results, investors will be watching whether Amgen's growth engines can continue offsetting biosimilar pressure on Prolia and Xgeva. Sustained momentum from Repatha, Evenity, Tezspire, Uplizna, and Imdelltra remains central to the company's ability to hit its raised 2026 targets. From what I see, this balance will determine how the stock performs in the months ahead.
A major catalyst on the horizon is MariTide, Amgen's investigational weight-loss therapy. With multiple late-stage studies underway, upcoming data readouts could materially shape the company's long-term narrative and investor sentiment, particularly given the intense competition in the obesity and cardiometabolic markets.
Cost discipline and margin trends also merit attention. While the company raised its outlook, investors will monitor operating expenses, tax rate assumptions, and free cash flow generation, which declined in the quarter. Any shifts in these metrics could influence how the market interprets the quality of future earnings growth. Finally, the pace of biosimilar launches and their impact on pricing will remain a key risk to watch across the legacy portfolio. I’m watching this closely as the numbers unfold.
Using AI Tools in My Research Process
In my analysis of names like Amgen, I often turn to Tickeron’s AI-powered tools to quickly scan for comparable opportunities and confirm technical patterns. The AI Screener stands out for its ability to filter thousands of stocks and ETFs by fundamentals, volatility, and AI-driven signals, helping surface ideas that might otherwise take hours to identify manually. It has become a practical part of how I cross-check earnings context against broader market trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AMGN in upward trend: 10-day moving average broke above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 44 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 147 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.530) is normal, around the industry mean (-1.476). P/E Ratio (28.696) is within average values for comparable stocks, (21.871). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.038) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
Advertisement